Fengqiong Liu1, Shanliang Ye2, Xin Zhu3, Xuesong He4, Shengzhou Wang4, Yinbao Li5, Jiang Lin3, Jingsu Wang4, Yonggan Lin4, Xin Ren2, Yong Li6, Zhaoqun Deng7. 1. Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University, Fuzhou, China. 2. Ganzhou Municipal Hospital, 49 Dagonglu, Ganzhou, 341000, People's Republic of China. 3. Department of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, 8 Dianlilu, Zhenjiang, 212000, People's Republic of China. 4. GanzhouShanjian Bio-Technology Co., Ltd., Ganzhou, China. 5. School of Pharmacrutical Sciences, Gannan Medical University, Ganzhou, China. 6. Ganzhou Municipal Hospital, 49 Dagonglu, Ganzhou, 341000, People's Republic of China. liyong@gdph.org.cn. 7. Department of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, 8 Dianlilu, Zhenjiang, 212000, People's Republic of China. zqdeng2002@163.com.
Abstract
BACKGROUND: To investigate the potential beneficial effect of fecal microbiota transplantation (FMT) on gastrointestinal symptoms, gut dysbiosis and immune status in discharged COVID-19 patients. CASE PRESENTATION: A total of 11 COVID-19 patients were recruited in April, 2020, about one month on average after they were discharged from the hospital. All subjects received FMT for 4 consecutive days by oral capsule administrations with 10 capsules for each day. In total, 5 out of 11 patients reported to be suffered from gastrointestinal symptoms, which were improved after FMT. After FMT, alterations of B cells were observed, which was characterized as decreased naive B cell (P = 0.012) and increased memory B cells (P = 0.001) and non-switched B cells (P = 0.012).The microbial community richness indicated by operational taxonomic units number, observed species and Chao1 estimator was marginally increased after FMT. Gut microbiome composition of discharged COVID-19 patients differed from that of the general population at both phylum and genera level, which was characterized with a lower proportion of Firmicutes (41.0%) and Actinobacteria (4.0%), higher proportion of Bacteroidetes (42.9%) and Proteobacteria (9.2%). FMT can partially restore the gut dysbiosis by increasing the relative abundance of Actinobacteria (15.0%) and reducing Proteobacteria (2.8%) at the phylum level. At the genera level, Bifidobacterium and Faecalibacterium had significantly increased after FMT. CONCLUSIONS: After FMT, altered peripheral lymphocyte subset, restored gut microbiota and alleviated gastrointestinal disorders were observe, suggesting that FMT may serve as a potential therapeutic and rehabilitative intervention for the COVID-19.
BACKGROUND: To investigate the potential beneficial effect of fecal microbiota transplantation (FMT) on gastrointestinal symptoms, gut dysbiosis and immune status in discharged COVID-19patients. CASE PRESENTATION: A total of 11 COVID-19patients were recruited in April, 2020, about one month on average after they were discharged from the hospital. All subjects received FMT for 4 consecutive days by oral capsule administrations with 10 capsules for each day. In total, 5 out of 11 patients reported to be suffered from gastrointestinal symptoms, which were improved after FMT. After FMT, alterations of B cells were observed, which was characterized as decreased naive B cell (P = 0.012) and increased memory B cells (P = 0.001) and non-switched B cells (P = 0.012).The microbial community richness indicated by operational taxonomic units number, observed species and Chao1 estimator was marginally increased after FMT. Gut microbiome composition of discharged COVID-19patients differed from that of the general population at both phylum and genera level, which was characterized with a lower proportion of Firmicutes (41.0%) and Actinobacteria (4.0%), higher proportion of Bacteroidetes (42.9%) and Proteobacteria (9.2%). FMT can partially restore the gut dysbiosis by increasing the relative abundance of Actinobacteria (15.0%) and reducing Proteobacteria (2.8%) at the phylum level. At the genera level, Bifidobacterium and Faecalibacterium had significantly increased after FMT. CONCLUSIONS: After FMT, altered peripheral lymphocyte subset, restored gut microbiota and alleviated gastrointestinal disorders were observe, suggesting that FMT may serve as a potential therapeutic and rehabilitative intervention for the COVID-19.
Authors: Takeshi Ichinohe; Iris K Pang; Yosuke Kumamoto; David R Peaper; John H Ho; Thomas S Murray; Akiko Iwasaki Journal: Proc Natl Acad Sci U S A Date: 2011-03-14 Impact factor: 11.205
Authors: Nelson Lee; David Hui; Alan Wu; Paul Chan; Peter Cameron; Gavin M Joynt; Anil Ahuja; Man Yee Yung; C B Leung; K F To; S F Lui; C C Szeto; Sydney Chung; Joseph J Y Sung Journal: N Engl J Med Date: 2003-04-07 Impact factor: 91.245
Authors: Tiffany Hensley-McBain; Alexander S Zevin; Jennifer Manuzak; Elise Smith; Jillian Gile; Charlene Miller; Brian Agricola; Michael Katze; R Keith Reeves; Colleen S Kraft; Stanley Langevin; Nichole R Klatt Journal: J Virol Date: 2016-04-29 Impact factor: 5.103
Authors: Mark J Cameron; Longsi Ran; Luoling Xu; Ali Danesh; Jesus F Bermejo-Martin; Cheryl M Cameron; Matthew P Muller; Wayne L Gold; Susan E Richardson; Susan M Poutanen; Barbara M Willey; Mark E DeVries; Yuan Fang; Charit Seneviratne; Steven E Bosinger; Desmond Persad; Peter Wilkinson; Larry D Greller; Roland Somogyi; Atul Humar; Shaf Keshavjee; Marie Louie; Mark B Loeb; James Brunton; Allison J McGeer; David J Kelvin Journal: J Virol Date: 2007-05-30 Impact factor: 5.103
Authors: Raphaela I Lau; Fen Zhang; Qin Liu; Qi Su; Francis K L Chan; Siew C Ng Journal: Nat Rev Gastroenterol Hepatol Date: 2022-10-21 Impact factor: 73.082
Authors: Laura Linares-García; María E Cárdenas-Barragán; Winston Hernández-Ceballos; Carlos S Pérez-Solano; Alizon S Morales-Guzmán; Danielle S Miller; Max Schmulson Journal: J Clin Gastroenterol Date: 2022-04-01 Impact factor: 3.062
Authors: Denise Battaglini; Chiara Robba; Andrea Fedele; Sebastian Trancǎ; Samir Giuseppe Sukkar; Vincenzo Di Pilato; Matteo Bassetti; Daniele Roberto Giacobbe; Antonio Vena; Nicolò Patroniti; Lorenzo Ball; Iole Brunetti; Antoni Torres Martí; Patricia Rieken Macedo Rocco; Paolo Pelosi Journal: Front Med (Lausanne) Date: 2021-06-04